-
-
-
-
-
-
-
클래스 A
-
-
-
© 2024 Ifvex
Korean (Korea)
최근 업데이트
-
The Manufacturer of Ibrutinib: A Key Player in Health ManagementIbrutinib is a targeted therapy that belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. By blocking the BTK protein, Ibrutinib prevents cancer cells from growing and dividing. This action makes it effective in treating cancers that depend on the B-cell receptor signaling pathway, such as CLL and MCL. The Need for Ibrutinib Blood cancers can significantly impact...좋아요, 공유, 댓글을 달려면 로그인이 필요해요!
-
더 많은 스토리